RxDoctor Payments Data

Mark Nyce, MD

Gastroenterology · Savannah, GANPI 1447205695

Payments from drug & device makers

$10,705in general payments, 2019–2025

Across 572 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$1K
  • Pfizer$692
  • Gilead$600
  • Takeda Pharmaceuticals U.S.A., Inc.$585
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$10,59099%
  • Education$1151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,705 in reported general payments places this provider in the 75th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$263,218
Medicare patients
645
Services billed
6,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin34$90,728
Humira(Cf) PenAdalimumab12$76,126
MotegrityPrucalopride Succinate40$33,124
LinzessLinaclotide54$32,264
TrulancePlecanatide19$15,532
Mesalamine26$14,601
Dexlansoprazole DrDexlansoprazole33$9,503
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates130$8,843
AprisoMesalamine12$5,961
Colesevelam Hcl61$4,884
Mesalamine ErMesalamine21$4,637
Pantoprazole Sodium229$2,986
Colestipol Hcl46$2,721
Omeprazole197$2,582
Budesonide DrBudesonide22$2,147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso$1,340$112,22165 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$585$33,12440 claims
AbbVieLinzess$3,490$32,26454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →